FindTrial
Sign In

Study on the Effect and Safety of 3-Weekly Intravenous Methylprednisolone Treatment in People with Active, Moderate-to-Severe Thyroid Eye Disease, Measuring Changes in Eye Activity and Appearance

Evaluation of the Efficacy and Safety of Intravenous Methylprednisolone Pulse Therapy in Patients with Active, Moderate to Severe Thyroid Eye Disease: A Prospective Observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/095289
Enrollment
20
Registered
2025-09-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H051- Chronic inflammatory disorders oforbit

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Aravind eye hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosis of moderate-to-severe active TED with CAS more than 3, with normal renal and liver function test and written consent form taken

Exclusion criteria

Exclusion criteria: Sight threatening TED, Previous orbital radiotherapy or decompression surgery, History of steroid intolerance or contraindication, Uncontrolled systemic illnesses, Pregnancy or lactation

Design outcomes

Primary

MeasureTime frame
High patient tolerance and compliance with the 3-weekly IV regimen due to fewer hospital visits and manageable side effects. Reduction in Clinical Activity Score (CAS) and VISA score indicating decreased orbital inflammation and disease activity. Timepoint: 12 months—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr MEGHA YOGESH JANGLE

Aravind Eye Hospital, Poonamallee

jayashreedr@aravind.org9104402696

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026